



FORM 7
MONTHLY PROGRESS REPORT FOR FEBRUARY

Name of CNSX Issuer: **Global Wellness Strategies Inc. (Formerly Redfund Capital Corp.)** (the "Issuer").

Trading Symbol: **LOAN**

Number of Outstanding Listed Securities: **16,555,134**

Date: **March 04, 2021**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the month of February, the Company announced a non-brokered private placement of up to 4,000,000 common shares at a price of \$0.25 per share for a total of \$1,000,000.

The Company issued 250,000 incentive stock options to certain Directors and Officers of the Company. The options are exercisable at \$0.255 for a period of five years.

On February 26, the Company signed a binding letter of intent with KaleidoUSA, a company based out of Washington state focused on myco-dosing and the production of consumer packaged products.

2. Provide a general overview and discussion of the activities of management.

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, hemp and CBD, healthcare-related target companies.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On February 26, the Company signed a binding letter of intent with KaleidoUSA, a company based out of Washington state focused on myco-dosing and the production of consumer packaged products.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable

8. Describe the acquisition of new customers or loss of customers.

Not Applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not Applicable

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

The Company issued 250,000 incentive stock options to certain Directors and Officers of the Company. The options are exercisable at \$0.255 for a period of five years.

The Company issued 700,450 common shares as compensation for certain consultants.

15. Provide details of any loans to or by Related Persons.

Not Applicable.

16. Provide details of any changes in directors, officers or committee members.

Eugene Hodgson resigned as a director of the Company as of February 22, 2021.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Due to the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", governments worldwide have been and are currently enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 4, 2021_____.

Meris Kott
Name of Director or Senior Officer

"Meris Kott"
Signature
CEO
Official Capacity

<i>Issuer Details</i>		For Month End	Date of Report
Name of Issuer		February 2021	YY/MM/D
Global Wellness Strategies Inc.			21/03/4
Issuer Address			
#1100-1111 Melville Street			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver BC V6E3V6			604.484.0355
Contact Name		Contact Position	Contact Telephone No.
Meris Kott		CEO	604.484.0355
Contact Email Address		Web Site Address	
info@globalwellnesstrategies.com >;		www.globalwellnesstrategies.com	